Brokers Set Expectations for CRSP FY2028 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Brookline Capital Markets dropped their FY2028 earnings per share (EPS) estimates for CRISPR Therapeutics in a research note issued on Monday, November 2nd. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn $6.73 per share for the year, down from their previous forecast of $6.86. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($4.44) per share. Brookline Capital Markets also issued estimates for CRISPR Therapeutics’ FY2029 earnings at $34.87 EPS and FY2030 earnings at $126.13 EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, November 2nd. The company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.09). The firm had revenue of $12.67 million for the quarter, compared to the consensus estimate of $14.75 million. CRISPR Therapeutics had a negative net margin of 1,812.07% and a negative return on equity of 24.96%. The firm’s revenue was up 1311.1% on a year-over-year basis.

Other equities analysts have also issued research reports about the company. HC Wainwright restated a “buy” rating on shares of CRISPR Therapeutics in a research note on Friday, October 9th. Needham & Company LLC restated a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday. Citigroup reaffirmed a “market outperform” rating on shares of CRISPR Therapeutics in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Thursday, October 15th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $55.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $65.75.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $49.99 on Wednesday. CRISPR Therapeutics has a twelve month low of $44.12 and a twelve month high of $63.45. The stock has a market capitalization of $4.83 billion, a price-to-earnings ratio of -10.55 and a beta of 1.92. The stock has a fifty day simple moving average of $53.86 and a two-hundred day simple moving average of $52.85. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 47,837 shares of the firm’s stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the sale, the chief executive officer owned 311,899 shares of the company’s stock, valued at $15,526,332.22. This trade represents a 13.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Simeon George sold 14,514 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $49.63, for a total value of $720,329.82. Following the completion of the transaction, the director owned 15,486 shares in the company, valued at $768,570.18. This trade represents a 48.38% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 93,558 shares of company stock valued at $4,881,663. 5.20% of the stock is currently owned by insiders.

Institutional Trading of CRISPR Therapeutics

Several hedge funds have recently modified their holdings of the company. Compass Financial Management LLC purchased a new position in shares of CRISPR Therapeutics in the 3rd quarter valued at approximately $25,000. Versant Capital Management Inc boosted its stake in CRISPR Therapeutics by 175.1% in the 2nd quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock worth $25,000 after purchasing an additional 296 shares in the last quarter. Ameritas Advisory Services LLC purchased a new stake in CRISPR Therapeutics during the 2nd quarter worth approximately $56,000. GAMMA Investing LLC grew its position in CRISPR Therapeutics by 92.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,246 shares of the company’s stock worth $69,000 after purchasing an additional 597 shares during the last quarter. Finally, Hollencrest Capital Management grew its position in CRISPR Therapeutics by 249.9% during the 1st quarter. Hollencrest Capital Management now owns 1,312 shares of the company’s stock worth $62,000 after purchasing an additional 937 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

More CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: CASGEVY generated $99 million in third-quarter revenue, up 30% from the prior quarter and nearly sixfold year over year. The therapy also gained pediatric approvals in the U.K., the UAE and Bahrain, expanding its potential reach. Company business update and results
• Positive Sentiment: The FDA granted CTX310 regenerative medicine designations, and the company flagged upcoming clinical data presentations for CTX310 and zugo-cel. These developments may provide pipeline catalysts, although they do not guarantee success. Company pipeline update
• Positive Sentiment: Needham reaffirmed its Buy rating and $82 price target, signaling analyst confidence in potential upside. Needham rating
• Neutral Sentiment: CRISPR Therapeutics appointed Siva Sakhamuri as chief technical officer. His manufacturing and technical-operations experience could help support development and commercialization, but the appointment’s financial impact is not yet clear. CTO appointment
• Negative Sentiment: CRSP reported a third-quarter loss of $1.15 per share, wider than the $1.06 consensus loss. Reported revenue of $12.67 million also fell short of the roughly $14.75 million estimate, despite strong year-over-year growth—an earnings miss that may pressure the shares. Quarterly results coverage

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.